GOSS — Gossamer Bio, Inc.

Gossamer Bio Q1 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: Gossamer ended Q1 2025 with $257.9 million in cash and cash equivalents, expected to fund operations into the first half of 2027.
• Revenue: Recognized revenue was $9.9 million, including $6.6 million from cost reimbursements related to the collaboration with Chiesi.
• Expenses: R&D expenses increased to $38 million from $32.4 million in Q1 2024. G&A expenses decreased to $8.7 million from $9.6 million in the prior year.
• Net Loss: The net loss for the quarter was $36.6 million, or $0.16 per share, an improvement from a net loss of $41.9 million, or $0.19 per share, in Q1 2024.

2. Strategic Updates and Business Highlights

• Seralutinib Development: Significant progress in the Phase III PROSERA study for pulmonary arterial hypertension (PAH) was highlighted, with enrollment nearing completion. As of May 12, 2025, 343 patients were enrolled, and the company anticipates full enrollment by early June.
• Patient Characteristics: The baseline characteristics of enrolled patients indicate a more severe population than previous studies, which Gossamer believes will enhance the likelihood of a positive treatment effect.
• PH-ILD Study: Gossamer is also advancing the SERANATA study for pulmonary hypertension associated with interstitial lung disease (PH-ILD), with plans to activate sites in Q4 2025.
• Collaboration with Chiesi: The partnership is crucial for the global registrational Phase III study in PH-ILD, validating Gossamer's approach to Seralutinib.

3. Forward Guidance and Outlook

• Top-Line Results: Gossamer expects to complete the blinded portion of the PROSERA study by Q4 2025, with top-line results anticipated in February 2026.
• Market Potential: The company is optimistic about the commercial prospects of Seralutinib, projecting it could become a multibillion-dollar franchise, particularly in the underserved PH-ILD market.

4. Bad News, Challenges, or Points of Concern

• Enrollment Delays: Although enrollment is progressing, the decision to allow additional patients into the PROSERA study has pushed the timeline for data reporting into 2026, which may affect investor sentiment.
• Competitive Landscape: The presence of existing therapies like sotatercept raises questions about market share and the potential for Seralutinib to differentiate itself.
• Regulatory Risks: The company must navigate the complexities of regulatory approvals, particularly in demonstrating clinical efficacy and safety compared to existing treatments.

5. Notable Q&A Insights

• Enrollment Strategy: Management emphasized the importance of enrolling the right patient population for the PROSERA study, which has led to a longer enrollment process but aims to increase the probability of success.
• Combination Therapy: There is interest in the potential for Seralutinib to be used in combination with sotatercept, although only a small number of patients are expected to be on background sotatercept in the PROSERA study.
• Market Dynamics: The company anticipates that by the time Seralutinib launches, a significant portion of the PAH patient population will have progressed beyond current treatments, creating a substantial market opportunity.
• Safety Profile: Gossamer is confident in Seralutinib's safety profile, which they believe will be a competitive advantage in the market.

Overall, Gossamer Bio is making significant strides in its clinical programs, particularly with Seralutinib, while navigating challenges related to enrollment timelines and competitive pressures in the pulmonary hypertension market.